Animal genetics group Genus has followed a 35% jump in adjusted profit with a £60m share buyback, as a joint venture deal in China slashed Debt and its gene-edited pig began to reach commercial markets.
Genus (LSE:GNS), the porcine and bovine genetics specialist, has spent the past month putting its strengthened Balance Sheet to work. Preliminary results for the year to 30 June 2026, published on 10 September, were accompanied by the launch of a £60m share buyback programme for the 2027 financial year, and the company has since issued a steady flow of transaction in own shares notices as purchases get under way.
Profits ahead of expectations
The results built on a July trading update in which Genus said its performance for the year was ahead of expectations. Revenue slipped 2% to £658.1m, reflecting the restructuring of its Chinese pig business, but adjusted profit before tax rose 35% to £100.2m and adjusted Earnings Per Share increased by the same proportion to 110.3p. The board proposed a final Dividend of 24.0p, taking the total for the year to 35.2p, a rise of 10%.
Statutory profit before tax rose to £310.5m from £28.5m, inflated by a £204.1m gain from the disposal of 51% of PIC China. Under that transaction, Genus transferred the Business into a joint venture with Beijing Capital Agribusiness, retaining a 49% stake and receiving £98m in net cash proceeds. The deal helped reduce net debt to £71.8m from £228.2m a year earlier, giving the group considerably more financial flexibility.
Both divisions contribute
The PIC porcine division remained the main engine of growth, with adjusted operating profit up 16% in constant currency. The bovine business, ABS, also improved markedly as its Value Acceleration Programme delivered around £9m of benefits during the year. Chief executive Jorgen Kokke described the year as one of significant strategic progress, and the board said the buyback reflected confidence in the group's prospects.
For the 2027 financial year, management expects resilient Underlying Profit growth despite the cyclical nature of agricultural markets. It said adjusted profit before tax should be in line with market expectations and above a normalised 2026 baseline of £90.3m, which strips out items that will not recur.
Gene-edited pig moves forward
A central part of the long-term Investment case is the PRRS-resistant pig, gene-edited to resist a virus that causes significant losses for pork producers worldwide. During the year Genus secured approvals or favourable determinations in Argentina, Canada, Uruguay and Peru, and commercialisation is now beginning in certain Latin American countries. The company cited survey work suggesting that 94% of consumers were open to buying gene-edited pork.
Genus said it continues to work towards approval in Mexico and Japan, which are important export destinations for US pork producers, and in China. Progress in those markets is widely regarded as a key Factor in how quickly the trait can be rolled out at scale in the United States, given the importance of export access to American farmers.
What to watch
Since the results, Genus has also reported director share dealings and the issue of new shares connected with employee schemes. The next scheduled milestones are the Annual General Meeting later in the autumn and interim results in early 2027, where investors will look for updates on buyback progress, the performance of the China joint venture and further regulatory decisions on the gene-edited pig. Market conditions in global pork and dairy remain a swing factor for near-term demand.






Please wait processing your request...